Genetic polymorphisms of PAI-1 and PAR-1 are associated with acute normal tissue toxicity in Chinese rectal cancer patients treated with pelvic radiotherapy
- PMID: 26347502
- PMCID: PMC4556037
- DOI: 10.2147/OTT.S83723
Genetic polymorphisms of PAI-1 and PAR-1 are associated with acute normal tissue toxicity in Chinese rectal cancer patients treated with pelvic radiotherapy
Abstract
Plasminogen activator inhibitor type 1 (PAI-1) and protease-activated receptor-1 (PAR-1) are crucial mediators of the intestinal microenvironment and are involved in radiation-induced acute and chronic injury. To evaluate whether genetic polymorphisms of PAI-1 and PAR-1 were predictors of radiation-induced injury in patients with rectal cancer, we retrospectively evaluated 356 rectal cancer patients who had received pelvic radiotherapy and analyzed the association of genetic polymorphisms of PAI-1 and PAR-1 with acute toxicities after radiotherapy. Acute adverse events were scored, including dermatitis, fecal incontinence (anal toxicity), hematological toxicity, diarrhea, and vomiting. The patients were grouped into grade ≥2 and grade 0-1 toxicity groups to analyze the acute toxicities. Genotyping of six single nucleotide polymorphisms (SNPs) of PAI-1 and PAR-1 was performed using TaqMan assays. A logistic regression model was used to estimate the odds ratios and 95% confidence intervals. Of the 356 individuals, 264 (72.5%) had grade ≥2 total toxicities; within this group, there were 65 (18.3%) individuals who reached grade ≥3 toxicities. There were 19.5% (69/354) and 36.9% (130/352) patients that developed grade ≥2 toxicities for diarrhea and fecal incontinence, respectively. The variant genotype GG of rs1050955 in PAI-1 was found to be negatively associated with the risk of diarrhea and incontinence (P<0.05), whereas the AG and GG genotypes of rs2227631 in PAI-1 were associated with an increased risk of incontinence. The CT genotype of PAR-1 rs32934 was associated with an increased risk of total toxicity compared with the CC allele. Our results demonstrated that SNPs in the PAI-1 and PAR-1 genes were associated with acute injury in rectal cancer patients treated with pelvic irradiation. These SNPs may be useful biomarkers for predicting acute radiotoxicity in patients with rectal cancer if validated in future studies.
Keywords: acute toxicity; biomarker; pelvic radiotherapy; polymorphism; rectal cancer.
Figures

Similar articles
-
[Association of single nucleotide polymorphisms in PAI-1 with breast cancer susceptibility and prognosis].Zhonghua Bing Li Xue Za Zhi. 2016 Aug 8;45(8):533-9. doi: 10.3760/cma.j.issn.0529-5807.2016.08.008. Zhonghua Bing Li Xue Za Zhi. 2016. PMID: 27510778 Chinese.
-
Accelerated hyperfractionated intensity-modulated radiotherapy for recurrent/unresectable rectal cancer in patients with previous pelvic irradiation: results of a phase II study.Radiat Oncol. 2014 Dec 11;9:278. doi: 10.1186/s13014-014-0278-3. Radiat Oncol. 2014. PMID: 25497847 Free PMC article. Clinical Trial.
-
[Impact of CCND1 A870G polymorphism on acute adverse events in postoperative rectal cancer patients treated with adjuvant concurrent chemoradiotherapy].Zhonghua Zhong Liu Za Zhi. 2013 Apr;35(4):268-72. doi: 10.3760/cma.j.issn.0253-3766.2013.04.006. Zhonghua Zhong Liu Za Zhi. 2013. PMID: 23985254 Clinical Trial. Chinese.
-
Dose-volume analysis of predictors for chronic rectal toxicity after treatment of prostate cancer with adaptive image-guided radiotherapy.Int J Radiat Oncol Biol Phys. 2005 Aug 1;62(5):1297-308. doi: 10.1016/j.ijrobp.2004.12.052. Int J Radiat Oncol Biol Phys. 2005. PMID: 16029785 Review.
-
Pelvic Complications After Prostate Cancer Radiation Therapy and Their Management: An International Collaborative Narrative Review.Eur Urol. 2019 Mar;75(3):464-476. doi: 10.1016/j.eururo.2018.12.003. Epub 2018 Dec 17. Eur Urol. 2019. PMID: 30573316
Cited by
-
Germline and Somatic Pharmacogenomics to Refine Rectal Cancer Patients Selection for Neo-Adjuvant Chemoradiotherapy.Front Pharmacol. 2020 Jun 17;11:897. doi: 10.3389/fphar.2020.00897. eCollection 2020. Front Pharmacol. 2020. PMID: 32625092 Free PMC article. Review.
-
Radiotherapy for unresectable locally advanced non-small cell lung cancer: a narrative review of the current landscape and future prospects in the era of immunotherapy.Transl Lung Cancer Res. 2020 Oct;9(5):2097-2112. doi: 10.21037/tlcr-20-511. Transl Lung Cancer Res. 2020. PMID: 33209629 Free PMC article. Review.
-
Chinese clinical practice guidelines for the prevention and treatment of radiation-induced rectal injury.Precis Radiat Oncol. 2023 Dec 25;7(4):237-255. doi: 10.1002/pro6.1217. eCollection 2023 Dec. Precis Radiat Oncol. 2023. PMID: 40336868 Free PMC article.
-
Atorvastatin Inhibits Endothelial PAI-1-Mediated Monocyte Migration and Alleviates Radiation-Induced Enteropathy.Int J Mol Sci. 2021 Feb 12;22(4):1828. doi: 10.3390/ijms22041828. Int J Mol Sci. 2021. PMID: 33673196 Free PMC article.
References
-
- Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90. - PubMed
-
- Siegel R, DeSantis C, Virgo K, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012;62(4):220–241. - PubMed
-
- Sauer R, Liersch T, Merkel S, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol. 2012;30(16):1926–1933. - PubMed
-
- Rödel C, Liersch T, Becker H, et al. German Rectal Cancer Study Group Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol. 2012;13(7):679–687. - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous